Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease PatientsJuly 26th, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease Patients A biopharmaceutical company announced the results of a Phase 1b of CERC-002.Article from GlobeNewswireShare This Story, Choose Your PlatformFacebookTwitterLinkedInPinterestEmail Related Posts Penn Announces Strategic Partnership with Longfellow Real Estate to Develop State-of-the-Art Life Sciences Facility in Philadelphia Stories From Our Region – May 2022 Stories From Our Region – April 2022 Regional Leaders Praise Greater Philadelphia’s Culture, Cuisine, and Quality of Life Stories From Our Region – March 2022
